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ABSTRACT 
IL-4 has been shown to have anti-tumoural activity in many cell lines. IL-4 needs to 
bind with IL-4 Receptor to exert its action. Down-regulation of IL-4 associated gp200-
MR6 expression has been associated with increasingly malignant tissues. 
Fifty-one pterygium and forty-one superior bulbar conjunctiva tissues from patients 
with pterygium, along with fourteen conjunctiva samples from pterygium-free subjects 
are subjected to immunohistochemical analysis to detennined the expression of IL-4, 
IL-4 receptor and IL-4 receptor associated gp200-MR6 molecule. 
Analysis of paired pterygium and conjunctiva samples revealed a lower percentage of 
pterygium stained positive for IL-4 and MR6. This trend is reversed for the expression 
of IL-4 receptor. None of these findings are statistically significant. 
This may represent a down-regulation of IL-4 and MR6 secondary to chronic actinic 
assaults. The up-regulation of IL-4R expression may be a compensatory mechanism to 
cope with less IL-4 concentration. The fact that differential expression of IL-4 and its 
receptors in pterygium and 'normal' conjunctiva tissue is not significant statistically 
points towards the field change sustained by conjunctiva when there is an actinic 
damage to the limbal stem cells from the very beginning. 
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The age of the patient and the size of pterygium tissues do not seem to influence the 
expression of IL-4, IL-4 receptor and IL-4 receptor associated gp-200 MR6 molecule in 
such tissues. Higher percentage of recurrent pterygium expressed IL-4 and MR6. 
Subjects with hypertension, diabetes and allergy disorders has less IL-4 and gp-200 
MR6 but more IL-4R expression on the pterygium tissues. Smoker seems to have higher 
staining for IL-4. This may again be the reflection of our body's immune mechanism 
coping with various different forms of stress. 
Higher percentage of conjunctiva of pterygium-free patients express IL-4R (p<O.05). 
Similar trend is true for MR6 molecule but statistically not significant. 
In the light of these evidences, more studies should be carried out to determine the 
presence of other cytokines or growth factors in ocular surface so that a composite 
picture of this possible autocrine loop that regulates the homeostasis of ocular surface 
can be elucidated. 
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ABSTRAK 
IL-4 mempunyai activiti anti-ketumbuhan dalam sebilangan besar aliran sel yang telah 
dikaji. Untuk menjalankan fungsinya, IL-4 mesti bergabung dengan reseptor IL-4 (IL-
4R). Penurunan regulasi expresi gp200-MR6 telah dikaitkan dengan peningkatan 
malignansi tisu. 
Sejumlah lima puluh satu tisu pterygium dan empat puluh satu tisu bulbar konjuntiva 
telah diambil daripada pesakit-pesakit yang menjalani pembedahan pembuangan tisu 
pterygium. Sejumlah empat belas sampel konjuntiva juga diperolehi daripada subjek 
yang tidak mempunyai ketumbuhan pterygium. Analisa imunohistokimia telah 
dijalankan ke atas semua sampel yang terkumpul untuk menentukan ekspresi IL-4, IL-
4R dan gp200-MR6. 
Analisis yang dijalankan ke atas sampel berkembar tisu pterygium dan konjuntiva 
mendapati peratusan keputusan positif yang lebih rendah untuk IL-4 dan gp200-MR6 
dalam tisu pterygium. Manakala tisu pterygium didapati mempunyai peratusan 
keputusan positif yang lebih tinggi untuk IL-4R berbanding tisu konjuntiva. Namun 
demikian, ia tidak signifikan (bererti) mengikut analisa statistik. 
Keputusan ini mungkin mencerminkan penurunan regulasi expresi IL-4 dan MR6 
disebabkan pendedahan aktinik yang kronik. Peningkatan regulasi ekspresi IL-4R 
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mungkin merupakan suatu mekanisma kompensatori tisu semasa menghadapi 
konsentrasi IL-4 yang berkurangan. Perbezaan keputusan expresi IL-4 serta reseptor-
reseptomya dalam tisu pterygium dan tisu konjuntiva yang tidak signifikan mengikut 
tafsiran statistik besar kemungkinan disebabkan oleh perubahan peralihan medan 
berperingkat yang dihadapi tisu konjuntiva apabila sel induk limbusnya mengalami 
kerosakan actinik dari peringkat permulaan lagi. 
Faktor umur subjek dan saiz tisu pterygium didapati tidak mempengaruhi ekspresi IL-4, 
IL-4R dan MR6 dalam tisu pterygium. Peratusan tisu pterygium yang rekuren 
(berulang) yand didapati positif terhadap IL-4 dan MR6 adalah lebih tinggi daripada 
tisu pterygium primer. Subjek yang mengalami penyakit darah tinggi, diabetis dan 
penyakit alergi didapati mempunyai expresi IL-4 dan MR6 yang kurang berbanding 
dengan subjek yang normal. Perokok pula mempunyai expresi IL-4 yang lebih tinggi. 
Semua ini mungkin menggambarkan mekanisma daya ketahanan tubuh kita apabila 
menghadapi tekanan yang pelbagai. 
Peratusan lebih tinggi untuk tisu konjuntiva daripada subjek yang tidak mempunyai 
ketumbuhan pterygium menunjukkan ekspresi IL-4R yang lebih tinggi. Keputusan ini 
adalah signifikan mengikut analisa ststistik. 
Sesungguhnya, daripada kesimpulan keputusan-keputusan yang diperolehi dalam kajian 
ini, lebih banyak kajian perIu dijalankan untuk menentukan kehadiran serta peranan 
sebenar yang dimainkan oleh pelbagai sitokin dan faktor ketumbuhan dalam tisu 
pennukaan okular. Ini diharapkan akan dapat memberi gambaran yang lebih jitu tentang 
kemungkinan kehadiran suatu lengkaran autokrin yang mengawal proses homeostasis 
pada pennukaan tisu ocular. 
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1. INTRODUCTION 
Pterygium is not just a degenerative disease, but may be a proliferative disorder of the 
ocular surface. This may explain the high incidence of recurrent rate after its primary 
excision. Studies have consistently shown that countries nearer the equator have higher 
rates of pterygium. A possible reason for this geographic variation is that the ultraviolet 
B irradiation may be one of the most important risk factors for the development of 
pterygium. 
While many treatment modalities have been attempted to manage pterygium, it is 
equally important to try to elucidate the consequences of chronic UV light exposure on 
this tissue. This will provide us with valuable information regarding the changes in its 
micro-environment which may form the basis of possible new and more effective 
treatment modalities. In the light of better understanding of the epithelial biology of the 
ocular surface and availability of improved materials and methods in immunological 
research, potential plausible pathogenesis of this tissue can be identified. 
This study involved the use of immunocytochemical technique to gauge the expression 
ofIL-4, IL-4 Receptor and IL-4 Receptor related gp200-MR6 molecule, the presence of 
all of which has been investigated and proven to playa role in the pathogenesis of 
malignancy in other tissues and other cell lines. Their potential role in pterygium has 
not been explored thus far. 
2 
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2. OBJECTIVES OF STUDY 
2.1 GENERAL OBJECTIVE 
The aim of this study is to investigate the expression and postulate the role of 
IL-4 and its receptors in the pathogenesis of pterygium 
2.2 SPECIFIC OBJECTIVES 
1. To compare the expression of IL-4, IL-4 receptor and MR6 molecule in 
pterygium and nonnal conjunctiva tissue unexposed to UV light in 
patients with pterygium. 
11. To compare the expression of IL-4, IL-4 receptor and MR6 molecule in 
pterygium in relation to the age of the subjects, size of the pterygium and 
other clinical parameters. 
111. To compare the expression of IL-4, IL-4 receptor and MR6 molecule in 
normal conjunctiva tissue unexposed to UV light in subjects with and 
without pterygium. 
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2.3 NULL HYPOTHESIS 
1. There is no significant difference of expression of IL-4, IL-4 receptor 
and IL-4 receptor related gp200-MR6 molecule in pterygium and normal 
conjunctiva tissue in patients with pterygium. 
ii. There is no significant difference of expression of IL-4, IL-4 receptor 
and IL-4 receptor related gp200-MR6 molecule in pterygium in relation 
to the age of the subjects, size of the pterygium and other clinical 
parameters. 
111. There is no significant difference of expression of IL-4, IL-4 receptor 
and IL-4 receptor related gp200-MR6 molecule in normal conjunctiva 
tissue unexposed to UV light in subj ects with and without pterygium. 
5 
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3. BACKGROUND 
Ever since Susruta recorded the removal of a pterygium lesion in 1000 BC (Jaros PA et 
ai, 1988), this triangular fold of vascularised bulbar conjunctiva still poses a challenge 
to the practising ophthalmologists and researchers alike. Its histology and the 
ultrastructure has been studied extensively (Duke-elder S, 1954; Spencer WH et ai, 
1985; Hogan MJ et ai, 1967; Austin P et ai, 1983) and hypothesis put forth suggesting 
its aetiopathogenesis (Moran DJ et ai, 1984; Karai I et ai, 1984; Wong WW, 1978; 
Pinkerton OD et ai, 1984), hoping to find a more satisfactory management of this 
disease process as it has a high recurrent rate after primary excision. 
Duke-Elder has defined pterygium as a degenerative and hyperplastic process (Duke-
Elder S, 1954) where there is accumulations of amorphous, eosinophilic, hyalinised or 
granular-appearing material resembling degenerated collagen interspersed with coiled or 
fragmented fibres resembling abnormal elastic tissue (Spencer WH et ai, 1985) which 
interestingly is resistant to the nonproteolytic enzyme elastase, hence the terms elastoid 
and elastotic degeneration (Cogan DG et ai, 1959). It is often found that the stromal 
fibrocytes are increased in number as if proliferating in response to injury. Minor 
aggregates of proteinaceous substance, acid mucopolysaccharide and calcific 
concretions are also seen in older lesion. 
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Austin P, lackobiec et al concluded that a large component of pingueculae and pterygia 
is the result of newly synthesised elastic fibre precursors with abnormal maturation 
(elastodysplasia) that undergo secondary degeneration (elastodystrophy) (Austin P et ai, 
1983). The histological features have uncanny resemblance to those found in 
pingueculae and in the dermis of sun-exposed skin. Clinically, pterygium differs from 
pinguecula by exhibiting progressive invasion of fibrovascular tissue into the cornea. 
This actinic elastotosis are widely believed to arise from an abnormal elastogenesis 
secondary to fibroblastic activation by UV radiation. (Spencer WH et ai, 1985; Ledoux-
Corbusier M et a11979) 
Immunologic basis for the pathogenesis of pterygium has gained substantial 
momentum in the last decade. In addition to the early demonstration of plasma cell and 
lymphocytes infiltration in the stroma with the presence of IgG and IgE, which is absent 
in normal conjunctiva (Austin P. et ai, 1983). Liu L et al have also demonstrated that 
most of the lymphocytes are T-cell (CD3+) and alteration of the helper-suppressor ratio 
from 1 :2.7 in the normal conjunctiva to 1: 1.5 in pterygium, which lead them to believe 
it to be a phenomenon of type 1,3 and 4 hypersensitivity (Liu L et ai, 1993). Mast cells 
count in pterygium was found to be twice as high as in normal conjunctiva (Nakagami T 
et ai, 1997, 1998). 
In the quest of finding growth factors in pterygium, Kria et al has demonstrated with 
immunohistochemical and ELISA analysis that basic fibroblast growth factor (b-FGF) 
is strongly expressed in tissue cultures from recurrent pterygium as the platelet-derived 
growth factor (PDGF) in primary pterygium. There is however only a weak expression 
of both transforming growth factor beta (TGF -~) and tumour necrosis factor alpha (TNF 
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a.). All four growth factors are expressed strongly in pterygium tissue in vivo. All these 
GFs were however sparse in nonnal conjunctival fibroblasts (Kria L et ai, 1998). These 
findings provide evidence that b-FGF may participate in recurrence and rapid growth of 
pterygium by its angiogenic activity. TGF-~, being a fibrogenic factor may enhance the 
fibrotic process. (Kria L et ai, 1998). 
TGF-~ family contains prototypic and potent cytokines involved in fibrosis (scarring) 
during wound repair processes (Border W A et ai, 1992; Roberts AB et ai, 1993; Grande 
JP et ai, 1997). They consist of 3 different isofonns and they exert their actions via 
binding with three respective receptors. 
Establishment of the limballocation of corneal epithelial stem cells has brought about 
the concept of limbal stem cell deficiency. (Schenner A et ai, 1986; Tseng SCG et ai, 
1989; Tseng SCG et aI, 1996). In nonnal subjects, the epithelial mass fonned at the 
limbus constitutes a growth pressure and acts as a junctional barrier to prevent 
conjunctival epithelial migration onto the corneal surface in the event of a total corneal 
epithelial defect. When there is an insult to this region, a spectrum of abnonnal corneal 
surfaces is produced (Chen JJY et ai, 1991). This can manifest as conjunctivalization 
with vascularization, chronic inflammation, destruction of the basement membrane and 
fibrous ingrowth. 
K work LS et al has demonstrated in his animal model for pterygium, that an albedo 
(indirect) light projected from the temporal sclera is focused and concentrated at the 
nasal limbus, suggesting that UV light might cause focal alteration of the limbal tissue 
thus causing pterygium fonnation (Kwork LS et ai, 1994). This can perhaps explained 
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the nasal bulbar conjunctiva predilection of pterygium and the intrinsic abnormalities in 
DNA repair as a result of UV irradiation as evident by a high incidence of microsatellite 
instability and loss of heterozygosity. (Spandidos DA et ai, 1997). 
Pterygium can indeed be locally invasive, and the pterygium epithelium exhibits 
varying degrees of abnormality, ranging from mild dysplasia to carcinoma in-situ (Clear 
AS et ai, 1979). Tan DTH et al and Dushku et al have independently in their 
immunohistochemical study with p53 monoclonal antibody found that there is increased 
nuclear p53 gene product in the limbal epithelium of pterygium but with little or no 
apoptosis. This, they concluded, is consistent with an activating mutation of p53 gene 
secondary to UV irradiation (Tan DTH et ai, 1997; Dushku N et ai, 1997). p53 is a 
tumour suppressor gene, it is the most common marker of human neoplastic growth. It 
is thought to act as a transcription factor that activates or represses the expression of 
growth-controlling genes and is abnormally expressed in a variety of human cancer 
(Greenblatt MS et ai, 1994) as well as in actinic skin lesions (Sim CS et ai, 1992). 
Dushku et al also demonstrated the expression of vimentin in limbal epithelium of 
pterygium, which is normally found in mesenchymal cells and migrating epithelial cells. 
(Dushku N et ai, 1994). In the related development, Kennedy Met al has demonstrated 
that ultraviolet Blight (UV B) does induce the production of multiple cytokines (IL-l, 
IL-6, IL-8 and TNFa) by the corneal stromal cells. (Kennedy Met ai, 1997). 
Interleukins (IL) as a part of the cytokines family were first described as a group of 
signalling polypeptides, controlling the activity of lymphoid and haemopoietic cells (0' 
Garra A, 1989a; 1989b ). Various human tumours have been shown to express receptors 
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for many different ILs ( McMillan et ai, 1995; Topp et ai, 1995; Moore et ai, 1999). 
Exposure of these cells to variety of ILs leads to positive or negetive receptor-mediated 
regulation of cell growth. In the recent years, however, emphasis has been on the 
possibility that human tumour cells of non-lymphoid origin may also be capable of 
producing and / or responding to some of these cytokines. For example, IL-1 (a. & ~) 
and IL-6 has been shown to stimulate the proliferation of certain tumour cell lines in 
vitro (Tsai S.C. et ai, 1987; Howard Met aI1982). 
IL of interest in this study is IL-4, a member of the cytokine family with multifunctional 
activities on a variety of cell lines. It is a glycoprotein of 129 amino acids with a 
molecular weight of 15 000 - 20 000 Dalton. IL-4 is glycosylated at two arginine 
residues (position 38 and 105) and contains six cysteine residues involved in disulfide 
bond formation, which is essential for its biological activity. 
IL-4 is secreted by activated CD4 T cell of Th 2 subset, also produced by mast cells and 
basophils. Initially described as a B-cell growth factor (Howard M et ai 1982), it has 
subsequently shown to have a wide spectrum of activities on T lymphocytes, 
macrophages, granulocytes and epithelial cells (O'Hara J et ai, 1987; Monroe JG et al 
1988; Thornhill MH et ai, 1990; Toi M et al 1991). Being a prototypic type 2 
immunoregulatory cytokine (Brown MA et aI, 1997; Chomarat P et al 1997), it 
modulates the production of cytokine by endothelial cells, monocytes and macrophages, 
also reducing inflammation by stimulating the production of monocytes IL-l Receptor 
antagonist (Chomarat P et al 1995) and soluble 'decoy' IL-l receptor (Calotta F et ai, 
1993). 
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IL-4 has been reported to exert anti-proliferative effect on some cancer cells. Hoon et ai 
have demonstrated that IL-4 alone or in combination with other cytokines could 
modulate cell surface Ag expression and inhibited growth of human melanoma cells in a 
dose-dependent manner, its anti-proliferative effect synergises with IFN-y. IL-4 also 
enhanced the anti-proliferative effect of TNF-a. and the additive effect was significantly 
more potent than the individual cytokines or IL-4 plus IFN-y (Hoon et ai1991). 
Accumulating data from transfection assays with the IL-4 gene or treatment of cell lines 
with IL-4 show that IL-4 has a potent anti-tumoural activity e.g. B.16 melanoma cell 
line in mice, mammary adenocarcinoma and Lewis Lung carcinoma (Zaloom Y et ai, 
1993; Tepper RI et ai, 1989). Providing the evidence that IL-4 gene -transfected CA 
cells can be used for CA immunotherapy (Ohira T et ai 1992). Synergism between IL-4 
production and other growth inhibitors has also been described (Thornhill MH et ai, 
1990). Expression of IL-4 can be studied using an IL-4 antibody with 
immunohistochemistry technique. (Figure 3.1) 
To enable IL-4 to exert its biological effects, it needs to bind with a specific IL-4 
receptor. The human IL-4 receptor has an extracellular domain of 207 amino acids, a 
transmembrane domain of 24 residues, and a large intracellular domain of 569 amino 
acids. The IL-4 receptor is a complex consisting of two chains. One chain is high 
affinity IL-4 binding (p140, a chain, CD 124) chain and the other chain is the y chain. 
The high affinity IL-4 binding chain belongs to the cytokine receptor superfamily. The 
cytoplasmic domain contains SerlPro-rich regions similar to those present in the IL-2 
receptor and GM-CSF receptor p-chains. (Callard R et ai, 1994). 
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The evidence of such vital marriage between the IL-4 and IL-4 receptor is elucidated in 
the study of proliferation of a number of breast cancer cell lines including anchorage-
dependent and independent breast cancer cell lines MCF-7 and MDA-MB-231 were 
inhibited by IL-4, which exerts its effect through IL-4Rs expressed on these cells. The 
mechanism of IL-4-induced growth inhibition in human breast cancer was thought to be 
the induction of apoptosis (Gooch et ai, 1998). 
Further support of IL-4 role in the immunological surveillance of tumour comes from 
the studies on the IL-4 receptor related gp200-MR6 molecule, using antibody for 
gp200-MR6 (Figure 3.2). The facts that gp200-MR6 expression is lost with increasing 
malignancy in lung and colonic CA, does suggest its role in tumour suppression 
(Tungekar G et ai, 1991; Kaklamanis L et ai, 1992). In breast Ca however, both 
upregulation and downregulation have been reported (Mat m et ai, 1993; AI Jabaari B 
et ai, 1989). Lorenzen et al suggested that the loss of IL-4R related gp200-MR6 
represent a mechanism of tumour escape from immune surveillance. To the best of our 
knowledge, the expression of IL-4 and IL-4 receptor and IL-4 receptor associated 
gp200-MR6 molecule on the ocular tissue has never been studied before. Thus, this 
study was conducted to establish the presence of these cytokines on the ocular surface. 
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IL-4 and its membrane bound receptor which 
also have a gp 200 MR 6 molecule 
I Anti-IL4 I 
Ab 
IL-4R 
IL-4R 
MR6 
IL-4 binds to its receptor 
site 
MR6 
Adding antibody(Ab) to the complex or free IL-4 willlead to binding of the Ab onto the IL-4 
molecule. The Ab can be identified under the microscope by conjugating it to a dye which will show 
up as immunoflourescein positive, thus facilitating the study ofIL-4 expression 
Figure 3.1 Diagrammatic representation of IL-4, IL-4 receptor and IL-4 
receptor associated gp-200 MR6 molecule with anti-IL-4 Ab 
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IL-4 and its membrane bound 
receptor which also have a gp 200 
MR 6 molecule 
MR6 
IL-4 binds to its receptor site 
Addition ofMR6 antibody 
MR 
GAb 
The Ab to MR6 will bind to the IL-4 receptor-related gp200 MR6 molecule. The Ab can then be 
identified under the microscope by conjugating it to a dye which will show up as 
immunoflourescent positive, thus facilitating the study the expression ofIL-4 Receptor. 
Figure 3.2 Diagramatic representation of IL-4, IL-4 receptor and MR6 with anti-
MR6Ab. 
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4. MATERIAL AND METHODS 
4.1 STUDY DESIGN 
This is a laboratory-based comparative study. All the laboratory work is done in 
the laboratory of Department of pathology and Department of hnmunology. 
4.2.1 POPULATION, TIME AND PLACE OF STUDY 
Study population: 
Period of study: 
Place of study: 
Patients attending eye clinic in Hospital USM and 
General Hospital Kota Bharu who have consented for 
pterygium excision. 
Patients undergoing extracapsular cataract extraction in 
Hospital USM. 
1st January 2000 to 30th November 2001 
Department of Ophthalmology, School of Medical 
Sciences, USM. 
Department of Ophthalmology, Hospital Kota Bharu. 
hnmunohistochemistry laboratory, Department of 
Pathology, USM 
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4.3 SAMPLING AND SAMPLE SIZE 
A convenient sampling size was taken as there was no previous study on 
similar subj ect. 
4.4 SELECTION CRITERIA 
4.4.1 INCLUSION CRITERIA 
All patients who underwent pterygium excision or cataract extraction with 
otherwise normal eye were included in the study. 
4.4.2 EXCLUSION CRITERIA 
The following cases were excluded from the study: 
a) Patients on long term (in the last six months) or current use of topical medicated 
preparations (all preparation except eye lubricants without any active 
ingredients), nasal spray (e.g. steroid etc.). 
b) Patients on systemic steroid therapy or any other systemic immunomodulating 
medication (e.g. systemic cyclosporin A ) or any form of chemotherapy. 
c) Patients with history of trauma or insult to the eye within the last 6 months. 
(postoperative, subconjunctival haemorrhage etc). 
d) Patients with hisoty of any form of conjunctivitis or inflammation in the eyes 
(uveitis etc). 
e) Contact lens wearers. 
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f) Patients who has any form of keratoplasty performed. 
g) Patients with a known history of autoimmune disorders. (rheumatoid arthritis, 
SLE etc.) 
4.5 CONSENT 
All participating patients were explained in-depth regarding the nature and 
objectives of this study and the potential complications associated with tissue 
harvesting. This was done in patients' native language or dialects with the aid of 
diagrammatic representations of the procedures. Written informed consent is 
then obtained from the willing subjects. (Appendix C) 
4.6 VARIABLES OBSERVED 
The units of variables recorded include demographic datas e.g. the age, sex and 
race of the patients involved. The laterality of the pterygium or conjunctiva 
excised is duly recorded. Also recorded is the status of the pterygium, whether it 
is a primary or recurrent lesion. The size of the pterygium is also measured with 
slitlamp in millimetre (from the limbus of the cornea perpendicularly to the head 
of the pterygium). Also recorded is the presence of systemic illness like 
diabetes, hypertension, evidence of allergy or asthma and smoking. 
(Data collection sheet - Appendix A and B) 
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4.7 SPECIMEN 
Excision of tissue for the specimen is done with written consent (Appendix C). 
Three groups of tissues are obtained. 
Group 1: 
Pterygium proper 
Group 2: 
Superior or inferior bulbar conjunctival tissue from patient with 
pterygium who undergone cataract extraction or patient undergoing 
pterygium excision with conjunctival transposition and consented for 
bulbar conjunctival biopsy. 
Group 3: 
Superior bulbar conjunctival tissue from patient who has undergone 
cataract extraction and no evidence of pterygium. 
4.7.1 STORAGE 
Specimens collected will be immediately put into a cryo-vial and snap freezed in 
a portable nitrogen tank before being transferred to nitrogen tank for storage. 
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Figure 4.1 Tissues stored in the cryovials while awaiting sectioning. 
Figure 4.2 Cryovials are stacked-up in a nitrogen tank preserving the tissues at 
-70°C. 
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4.8 DEFINITION OF TERMS: 
a. Diabetes Mellitus- records of diabetic treatment or newly diagnosed diabetes 
with a fasting whole blood concentration of over 6.7mmolll, or a random value 
exceeding 10mmolll. 
b. Hypertension- clear records of treatment for hypertension or newly diagnosed 
hypertension defined as blood pressure recording of systolic more than 
140mmHg and/or diastolic of more than 90mmHg sustained over three 
consecutive recordings at least 6 hours apart. 
c. Allergy- clear history and/or record of treatment of allergy disorders. Clear 
history or clinical sign and symptom of allergy illness, ego acute exacerbation of 
bronchial asthma, allergic conjunctivitis, allergic rhinitis, history of urticaria or 
rashes after food or drug ingestion etc. 
d. Smoking- Clear history of active smoking or long duration of cigarette smoking 
(e.g. more than 6 months). 
e. Superior bulbar conjunctiva-- a small 3mm X 3mm conjunctival tissue harvested 
anywhere from eleven to one O'clock positions. 
f. Inferior bulbar conjunctiva-a small 3mm X 3mm conjunctival tissue harvested 
anywhere from five to seven O'clock positions. 
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4.9 ETIDCAL APPROVAL 
This Research protocol and methodology has been approved by the Research 
and Ethics Committee, School of Medical Sciences, Universiti Sains Malaysia. 
Reference: USM/PPSP®lEthics Com.l200 1 [54.4(4)] 
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4.10 IMMUNOmSTOCHEMISTRY - MATERIALS AND METHOD 
4.10.1 TISSUE SECTIONING 
Frozen pterygium tissue was embedded in Optimum Cold Temperature (OCT) 
compound and allowed to set on a chuck inside the cryotome before sectioning. 
The temperature inside the cryotome is maintained at -28°C at all time. 
Longitudinal sections of the tissue was then performed with cryotome (Leica 
CM 1850) to achieve a thickness of 51lm. 
Figure 4.3 Tissue is sectioned at a thickness of 51lm with the cryostats. 
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4.10.2 STAINING 
All specimens will be subjected to routine eosin-hematoxylin staining for better 
morphology interpretation. Standard immunohistochemical study is performed 
using Strep!.Avidin-biotin complex/HRP procedure with specificity controls. 
Figure 4.4 Staining station where the tissue sections are subjected to H&E 
staining and dehydration process 
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